



December 2017 Newsletter

Volume 5 Issue 11

A Letter from the Founder, Dr. Christine Brezden- Masley

Dear CCTC Members,

Since the launch of the CCTC in 2011, the consortium has remarkably expanded to over 260 members across 31 institutions, including 12 of the major cancer centres in Ontario.

We greatly value any input, feedback, and suggestions in order to make your experience with the site as user-friendly as possible. E-mail us at cometrials@smh.ca and we will be more than happy to assist.

Sincerely,

Dr. Christine Brezden-Masley
Founder, CCTC

A Letter from the Project Manager, Nicole Veloce

Hello CCTC Members,

Thank you to all our members for your continued support.

Please feel free share CCTC with your oncology colleagues. We are always happy to have new members join the CCTC network! CCTC is continuing to grow with 270 members and 31 institutions.

If you have an accruing trial you would like to highlight, please email cometrials@smh.ca to nominate it to be one of our next *Trials of the Month*.

As always, please contact me at cometrials@smh.ca any time with questions, comments or concerns.

Kind Regards,

Nicole Veloce
Project Manager, CCTC

ARTICLE RECOMMENDATION

Building trust and diversity in patient-centered oncology clinical trials: An integrated model

Hurd TC, Kaplan CD, Cook ED, Chilton JA, Lytton JS, Hawk ET, Jones LA

Clinical Trials; 14:2.

DOI: 10.1177/1740774516688860, Published February 2017

Purpose: Trust is the cornerstone of clinical trial recruitment and retention. Efforts to decrease barriers and increase clinical trial participation among diverse populations have yielded modest results. There is an urgent need to better understand the complex interactions between trust and clinical trial participation. The process of trust-building has been a focus of intense research in the business community. Yet, little has been published about trust in oncology clinical trials or the process of building trust in clinical trials. Both clinical trials and business share common dimensions. Business strategies for building trust may be transferable to the clinical trial setting. This study was conducted to understand and utilize contemporary thinking about building trust to develop an Integrated Model of Trust that incorporates both clinical and business perspectives.

Methods: A key word-directed literature search of the PubMed, Medline, Cochrane, and Google Search databases for entries dated between 1 January 1985 and 1 September 2015 was conducted to obtain information from which to develop an Integrated Model of Trust.

Results: Successful trial participation requires both participants and clinical trial team members to build distinctly different types of interpersonal trust to effect recruitment and retention. They are built under conditions of significant emotional stress and time constraints among people who do not know each other and have never worked together before. Swift Trust and Traditional Trust are sequentially built during the clinical trial process. Swift trust operates during the recruitment and very early active treatment phases of the clinical trial process. Traditional trust is built over time and operates during the active treatment and surveillance stages of clinical trials. The Psychological Contract frames the participants' and clinical trial team members' interpersonal trust relationship. The "terms" of interpersonal trust are negotiated through the psychological contract. Contract renegotiation occurs in response to cyclical changes within the trust relationship throughout trial participation.

Conclusions: The Integrated Model of Trust offers a novel framework to interrogate the process by which diverse populations and clinical trial teams build trust. To our knowledge, this is the first model of trust-building in clinical trials that frames trust development through integrated clinical and business perspectives. By focusing on the process, rather than outcomes of trust-building diverse trial participants, clinical trials teams, participants, and cancer centers may be able to better understand, measure, and manage their trust relationships in real time. Ultimately, this may foster increased recruitment and retention of diverse populations to clinical trials.

TRIALS SNAPSHOT

Trial Type	Any Malignancy	Breast	CNS	GI	GU	GYN	Head & Neck	Heme	Lung	Mel	Skin	Total
Imaging Study	-	-	-	-	2	-	-	1	-	-	-	3
Observational	1	2	-	-	1	1	-	1	-	-	-	6
Prevention	-	-	-	1	-	-	-	1	-	-	-	2
Radiation	-	3	-	3	5	-	1	-	6	-	-	18
Supportive Care	1	5	-	-	-	-	-	-	-	-	-	6
Surgical Therapy	-	1	1	-	1	1	-	-	-	-	-	4
Systemic Therapy	1	9	1	13	20	6	2	9	9	7	1	78
Therapeutic	-	1	-	-	2	1	-	3	-	-	-	7
TOTAL	3	21	2	17	31	9	3	15	15	7	1	124



December 2017 Newsletter

Volume 5, Issue 11

TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Site(s)
Breast	<u>IMpassion 131</u>	A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer	<ul style="list-style-type: none"> • Metastatic • Systemic Therapy 	London Health Sciences Centre Odette Cancer Centre
GU	<u>STRONG</u>	An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.	<ul style="list-style-type: none"> • Bladder Cancer • Advanced • Systemic Therapy 	London Health Sciences Centre
Heme	<u>Celgene AZA MDS</u>	A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia Due to IPSS Lower-Risk Myelodysplastic Syndromes	<ul style="list-style-type: none"> • Myelodysplastic syndromes • Untreated • Therapeutic Therapy 	Odette Cancer Centre Royal Victoria Regional Health Centre
GYN	<u>Garnet</u>	A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors	<ul style="list-style-type: none"> • Endometrial/Uterine Cancer • Advanced • Systemic Therapy 	London Health Sciences Centre
Lung	<u>NCIC.BR.31</u>	A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer	<ul style="list-style-type: none"> • Non-Small Cell • Adjuvant • Systemic Therapy 	Kingston General Hospital Humber River Regional Hospital London Health Sciences Centre Southlake Regional Health Centre
Mei	<u>Trilogy</u>	A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma	<ul style="list-style-type: none"> • Melanoma • Stage III/IV • Systemic Therapy 	London Health Sciences Centre
GI	<u>HALO-109-301</u>	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	<ul style="list-style-type: none"> • Pancreatic Cancer • Stage IV • Systemic Therapy 	Royal Victoria Regional Health Centre



[Click here to NOMINATE your trial for Trials of the Month!](#)



MEMBERSHIP UPDATES

272 members

31 institutions

124 accruing trials



ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street
Toronto, ON Canada
M5B 1W8

comettrials@smh.ca

(416) 809-3915

@COMET_Trials

www.comettrials.com

INSTITUTIONS

Institution	Location	Members	Trials
Cambridge Memorial Hospital	Cambridge	3	4
Grand River Hospital	Waterloo	9	1
Humber River Regional Hospital	Toronto	5	5
Kingston General Hospital	Kingston	4	25
Juravinski Cancer Centre	Hamilton	7	-
Lakeridge Health Corporation	Oshawa	21	-
London Health Sciences Centre	London	9	67
Mackenzie Health Hospital	Richmond Hill	6	-
Markham Stouffville Hospital	Markham	4	1
Mount Sinai Hospital	Toronto	2	5
North York General Hospital	Toronto	14	7
Odette Cancer Centre/Sunnybrook	Toronto	53	37
Ontario Institute for Cancer Research	Toronto	4	-
Ottawa Hospital	Ottawa	2	-
Princess Margaret Cancer Centre	Toronto	23	1
Quinte Health Care	Belleville	1	-
Rouge Valley Health System	Ajax	3	-
Royal Victoria Regional Health Centre	Barrie	23	16
Scarborough General Hospital	Toronto	2	-
Southlake Regional Health Centre	Newmarket	19	11
St. Joseph's Health Centre	Toronto	4	-
St. Joseph's Healthcare	Hamilton	4	-
St. Michael's Hospital	Toronto	15	4
Sudbury Regional Hospital	Sudbury	1	-
Thunder Bay Regional	Thunder Bay	2	-
Toronto General Hospital	Toronto	3	1
Toronto East General Hospital	Toronto	6	1
Trillium Health Partners	Mississauga	17	-
William Osler Health Systems	Brampton	4	-
Windsor Regional Hospital	Windsor	1	-
Wingham and District Hospital	Wingham	1	-